On day 21 following the first injection of the test reagents, aCX73 (average tumor volume 342.1 mm3, P < 0.05) and aCX82 (average 336.1 mm3, P < 0.05) achieved a statistically significant reduction of tumor volumes compared to the negative control antibody Her2-13C1 (average 451.6 mm3). Here, ERBB2 is linked to neoplasm.